Cromatina/Epigenética
Os inibidores de cromatina/epigenética são compostos que modulam a estrutura e função da cromatina ou interferem em modificações epigenéticas, como a metilação do DNA e a modificação de histonas. Esses inibidores são ferramentas essenciais para estudar a regulação da expressão gênica e o papel da epigenética em doenças como o câncer, distúrbios neurológicos e anomalias do desenvolvimento. Ao direcionar os processos epigenéticos, esses inibidores podem alterar os padrões de expressão gênica e oferecer novas vias terapêuticas. Na CymitQuimica, oferecemos uma ampla seleção de inibidores de cromatina/epigenética de alta qualidade para apoiar sua pesquisa em biologia molecular, genética e epigenética.
Subcategorias de "Cromatina/Epigenética"
Foram encontrados 2235 produtos de "Cromatina/Epigenética"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
MAT2A-IN-16
CAS:<p>MAT2A-IN-16 is a MAT2A inhibitor that effectively suppresses the proliferation of MTAP-/-HCT-116 cells, with an IC50 value of 20 nM.</p>Fórmula:C23H17ClN6OCor e Forma:SolidPeso molecular:428.874LSD1/2-IN-4
<p>LSD1/2-IN-4, a PCPA derivative, inhibits LSD1 (Ki 0.11 μM) & LSD2 (Ki 130 μM), potentially useful in T-cell leukemia research.</p>Fórmula:C9H8BrF2NCor e Forma:SolidPeso molecular:248.07PRMT5-IN-49
CAS:<p>PRMT5-IN-49 (Compound 4b16) is an inhibitor of PRMT5.</p>Fórmula:C19H22N2O2Cor e Forma:SolidPeso molecular:310.39MAT2A-IN-18
CAS:<p>MAT2A-IN-18 (Compound 15) is an inhibitor of methionine adenosyltransferase 2A (MAT2A) with an IC50 of 50 nM or less.</p>Fórmula:C17H13ClN4OCor e Forma:SolidPeso molecular:324.764JAK1-IN-9
CAS:<p>JAK1-IN-9 (compound 23a) is a potent, selective inhibitor of JAK1, demonstrating an IC50 of 72 nM.</p>Fórmula:C16H13IN6Cor e Forma:SolidPeso molecular:416.22NSD2-PWWP1-IN-1
CAS:<p>NSD2-PWWP1-IN-1 (compound 31) is a potent inhibitor of NSD2-PWWP1 with an IC50 value of 0.64 µM, demonstrating potential applications in cancer research.</p>Fórmula:C28H30N4Cor e Forma:SolidPeso molecular:422.565NSD2-PWWP1-IN-2
CAS:<p>NSD2-PWWP1-IN-2 (compound 33) is a potent NSD2-PWWP1 inhibitor, exhibiting an IC50 value of 1.49 µM, indicating its potential utility in cancer research.</p>Fórmula:C29H30N4Cor e Forma:SolidPeso molecular:434.575MAT2A-IN-21
CAS:<p>MAT2A-IN-21 (compound 28) is a potent inhibitor of methionine adenosyltransferase 2A (MAT2A), with an IC50 of 49 nM. It selectively inhibits cancer cells with MTAP deficiency.</p>Fórmula:C26H20F2N4O2Cor e Forma:SolidPeso molecular:458.459MAT2A-IN-20
CAS:<p>MAT2A-IN-20 (Compound A49) is an inhibitor of methionine adenosyltransferase 2A (MAT2A) with an IC50 of ≤50 nM. It also inhibits human UGT1A1 with an IC50 of 28.45 μM. Additionally, MAT2A-IN-20 exhibits antitumor activity in mouse models.</p>Fórmula:C26H24F2N6O4Cor e Forma:SolidPeso molecular:522.503HDAC-IN-27
<p>HDAC-IN-27 is a potent and orally active inhibitor of HDAC Class I (0.43 nM - 3.01 nM for HDAC1-3).</p>Fórmula:C20H22N4O2Cor e Forma:SolidPeso molecular:350.41(rac)-Talazoparib
CAS:<p>(rac)-Talazoparib ((rac)-BMN-673) (Compound 47) is an orally active inhibitor of PARP1/2, with Ki values of 1.2 nM and 0.87 nM, respectively. It inhibits cellular PARylation at an EC50 of 2.51 nM. This compound leads to the accumulation of DNA damage and suppresses the proliferation of BRCA1/2-mutated MX-1 and Capan-1 cells, with IC50 values of 0.3 nM and 5 nM, respectively. Additionally, (rac)-Talazoparib exhibits antitumor activity in mouse models.</p>Fórmula:C19H14F2N6OCor e Forma:SolidPeso molecular:380.3515-AIQ hydrochloride
CAS:<p>5-AIQ hydrochloride is a water-soluble PARP-1 inhibitor and serves as a vital functional group in various medications. It mitigates tissue damage associated with hepatic ischemia-reperfusion, making it valuable for research into conditions related to liver ischemia-reperfusion.</p>Fórmula:C9H9ClN2OCor e Forma:SolidPeso molecular:196.634NVS-BPTF-1
CAS:<p>NVS-BPTF-1 is a specific inhibitor of bromodomain and PHD finger containing transcription factor (BPTF), exhibiting a dissociation constant (K_D) of 71 nM [1].</p>Fórmula:C26H28FN7O3SCor e Forma:SolidPeso molecular:537.61SRI-43265
CAS:<p>SRI-43265 (compound 40) inhibits the dimerization of human antigen R protein (HuR), which is involved in cancer and inflammation pathogenesis [1].</p>Fórmula:C19H20N6OCor e Forma:SolidPeso molecular:348.4MAT2A-IN-17
CAS:<p>MAT2A-IN-17 is a potent inhibitor of MAT2A, with an IC50 of less than 100 nM. MAT2A-IN-17 is applicable in cancer research.</p>Fórmula:C23H18F3N7OCor e Forma:SolidPeso molecular:465.431HDAC1-IN-3
<p>HDAC1-IN-3 is a potent inhibitor of Pf HDAC1.</p>Fórmula:C22H24ClN7O2Cor e Forma:SolidPeso molecular:453.92BET/Aurora kinase-IN-1
CAS:<p>BET/Aurora kinase-IN-1 (Compound 38) is a dual inhibitor of BET and Aurora kinases. It exhibits antiproliferative activity against various tumor cell lines and demonstrates significant antitumor efficacy in xenograft models of renal cell carcinoma and colon cancer, with tumor growth inhibition (TGI) rates of 45.99% and 53.06%, respectively.</p>Fórmula:C25H30FN7OCor e Forma:SolidPeso molecular:463.55HDAC-IN-87
CAS:<p>HDAC-IN-87 (Compound XII6) is a non-selective HDAC inhibitor with pIC50 values of 6.9 for HDAC4 and 5.8 for HDAC6. It exhibits fungicidal activity against P. sorghi and P. pachyrhizi. The acute oral LD50 in both male and female rats is greater than 500 mg/kg.</p>Fórmula:C13H7F5N4O2SCor e Forma:SolidPeso molecular:378.277HYDAMTIQ
CAS:<p>HYDAMTIQ, a PARP-1/2 inhibitor (IC 50 : 29-38 nM), exhibits a range of pharmacological effects including anticancer, anti-inflammatory, and ischemic protective properties. It effectively reduces pulmonary PARP activity and alleviates symptoms such as allergen-induced cough and dyspnea while also diminishing bronchial hyperresponsiveness to methacholine. Moreover, HYDAMTIQ shows potent tumor suppressor activity in various cancers such as ovarian, breast, prostate, pancreatic, and glioblastoma multiforme. Demonstrating in vivo efficacy, HYDAMTIQ has been tested in animal models for conditions like cerebral ischemia, asthma, and cancer [1].</p>Fórmula:C14H14N2O2SCor e Forma:SolidPeso molecular:274.34BRD4 D1-IN-1
<p>BRD4 D1-IN-1 selectively inhibits BRD4 D1 (IC50 <0.092 μM, Kd 18 nM) with >500-fold specificity versus D2.</p>Fórmula:C32H37F3N6OCor e Forma:SolidPeso molecular:578.67PHD2-IN-4
CAS:<p>PHD2-IN-4 (compound 1) is an inhibitor of PHD2, with an IC50 of 4 nM. It is utilized in research related to chronic kidney disease.</p>Fórmula:C21H19N5O3Cor e Forma:SolidPeso molecular:389.407SARS-CoV-2 nsp14-IN-1
<p>SARS-CoV-2 nsp14-IN-1 inhibits Nsp14 Mtase with an IC50 of 0.061 μM, affecting multiple substrates.</p>Fórmula:C20H20N6O5SCor e Forma:SolidPeso molecular:456.48SIRT-IN-6
CAS:<p>SIRT-IN-6 (Compound 14) is a pan-inhibitor of SIRT1/2/3 with an IC50 value of >50 μM. It shows potential as a research agent for studies involving metabolic disorders, inflammation, cancer, and neurodegenerative diseases.</p>Fórmula:C7H4ClN3OSCor e Forma:SolidPeso molecular:213.644Milpecitinib
CAS:<p>Milpecitinib (Compound 21a) is a potent and selective Janus tyrosine kinase (JAK) inhibitor with anti-inflammatory properties. It shows promise for research in cancer and inflammatory diseases.</p>Fórmula:C20H20N4O2SCor e Forma:SolidPeso molecular:380.463HDAC11-IN-2
CAS:<p>HDAC11-IN-2 (compound B6) is a highly selective inhibitor of Histone Deacetylase 11 (HDAC11). It demonstrates IC50 values of 51.1 ×10^-3 μM for HDAC11 and 5 μM for HDAC8. HDAC11-IN-2 reduces de novo lipogenesis (DNL) and enhances fatty acid oxidation, which alleviates hepatic lipid accumulation and pathological symptoms in MASLD mice. By inhibiting HDAC11, HDAC11-IN-2 enhances the phosphorylation of AMPKα1 at the Thr172 site, thereby modulating de novo lipogenesis and fatty acid oxidation in the liver.</p>Fórmula:C25H35N3O3Cor e Forma:SolidPeso molecular:425.564PRMT5-IN-48
CAS:<p>PRMT5-IN-48 (compound D3) is an orally active PRMT5 inhibitor with an IC50 of 20.7 nM, displaying antitumor activity. It effectively suppresses the growth of various cancer cells, induces apoptosis, and causes cell cycle arrest at the G0/G1 phase. PRMT5-IN-48 is applicable for research in non-Hodgkin's lymphoma (NHL).</p>Fórmula:C30H37N5O3Cor e Forma:SolidPeso molecular:515.646GSK3368715 3HCl
CAS:<p>GSK3368715, a potent inhibitor of type I protein arginine methyltransferases (PRMT), could inhibit PRMT1, 3, 4, 6 and 8 with Kiapp vaules ranging from 1.5 to 81</p>Fórmula:C20H41Cl3N4O2Pureza:98%Cor e Forma:SolidPeso molecular:475.92DS79932728
CAS:<p>DS79932728 is an orally active inhibitor of G9a and GLP, with IC50 values of 12.6 nM and 75.7 nM, respectively. It induces the production of γ-globin, thereby increasing fetal hemoglobin (HbF) levels. In cynomolgus monkey models, DS79932728 enhances the proportion of F-reticulocytes (F-rets) and shows good oral absorption characteristics.</p>Fórmula:C19H25N3OCor e Forma:SolidPeso molecular:311.421JAK3-IN-7
CAS:<p>JAK3-IN-7 is a potent and selective JAK3 inhibitor (IC50<0.01 μM) for the treatment of rejection in organ transplantation, graft-versus-host reaction after</p>Fórmula:C17H20N6OPureza:98.81%Cor e Forma:SolidPeso molecular:324.38LNK01004
CAS:<p>LNK01004 is a JAK inhibitor that exhibits potent inhibitory effects on JAK1 (IC50: 10 nM), JAK2 (IC50: ＜0.51 nM), and TYK2 (IC50: 1.0 nM). It can concurrently inhibit multiple cytokine-induced p-STAT signaling pathways and is applicable for research on diseases such as atopic dermatitis.</p>Fórmula:C26H31N7O2Cor e Forma:SolidPeso molecular:473.57HIF-2α-IN-5
CAS:<p>HIF-2α-IN-5 is a potent HIF-2α inhibitor with an IC 50 of < 50 nM [1].</p>Fórmula:C15H12F4O3S2Cor e Forma:SolidPeso molecular:380.38PRMT5-IN-37
CAS:<p>PRMT5-IN-37 (compound 29), an orally active inhibitor of PRMT5, is utilized for cancer research.</p>Fórmula:C21H15F4N5O2Cor e Forma:SolidPeso molecular:445.37JTZ-951 HCl
CAS:<p>JTZ-951 is a potent and orally active inhibitor of hypoxia inducible factor prolyl hydroxylase (PHD).</p>Fórmula:C17H17ClN4O4Pureza:98%Cor e Forma:SolidPeso molecular:376.79lirucitinib
CAS:<p>Lirucitinib is a JAK inhibitor known for its anti-inflammatory properties.</p>Fórmula:C16H25N5OSCor e Forma:SolidPeso molecular:335.468FY-56
<p>FY-56: potent, selective LSD1/KDM1A inhibitor (IC50=42nM); differentiates MOLM-13/MV4-11 cells; promising for AML research.</p>Fórmula:C23H19FN2O3Cor e Forma:SolidPeso molecular:390.41DDO-3055
CAS:<p>DDO-3055 is an orally active PHD2 inhibitor utilized in studies related to anemia associated with chronic kidney disease.</p>Fórmula:C17H13ClN2O5Cor e Forma:SolidPeso molecular:360.749LSD1-IN-39
CAS:<p>LSD1-IN-39 (Compound 14) is a reversible inhibitor of LSD1 with an IC50 of 0.18 μM, showing broad-spectrum antiproliferative activity against cancer cells, inhibiting HepG2 cell migration, and suppressing epithelial-mesenchymal transition. Additionally, LSD1-IN-39 exhibits antitumor activity in mouse models.</p>Fórmula:C25H30N2O7Cor e Forma:SolidPeso molecular:470.515AMPK activator 16
CAS:<p>AMPK activator16 (compound 6) functions as an AMP-activated protein kinase (AMPK) inhibitor. It interacts effectively with crucial AMPK residues, significantly activating the enzyme. In N2a cells, AMPK activator16 enhances the expression of phosphorylated AMPK (p-AMPK) and its downstream signaling proteins, such as phosphorylated ACC (Acetyl-CoA Carboxylase) and phosphorylated raptor (p-raptor).</p>Fórmula:C23H20ClNO5SCor e Forma:SolidPeso molecular:457.927CREB-IN-1 TFA
<p>CREB-IN-1 TFA: Potent oral CREB inhibitor, IC50 of 0.18 μM, suppresses breast cancer cell growth.</p>Cor e Forma:SolidSTR-V-53
CAS:<p>STR-V-53, an HDAC inhibitor (IC50 in nM), increases histone acetylation in tumor cells by inhibiting these enzymes, thereby regulating gene expression. STR-V-53 inhibits tumor growth and induces apoptosis [1].</p>Fórmula:C21H30N4O8Cor e Forma:SolidPeso molecular:466.48Purinostat
CAS:<p>Purinostat is a selective inhibitor of HDACI/IIb with potential anti-leukemic properties. Its mesylate form, Purinostat mesylate, is effective at inhibiting the survival of Ph+ leukemic cells and CD34+ leukemic cells derived from CML patients. Purinostat mesylate targets HDACI/IIb, impacting several crucial factors for leukemia stem cell (LSC) survival, such as c-Myc, β-Catenin, E2f, Ezh2, Alox5, and mTOR. Additionally, Purinostat mesylate enhances glutamate metabolism in LSCs by increasing GLS1.</p>Fórmula:C23H26N10O3Cor e Forma:SolidPeso molecular:490.518LSD1-IN-15
<p>LSD1-IN-15 inhibits LSD1, MAO-A/B with IC50s: 0.149, 0.028, 0.327 μM; arrests LNCaP cancer cell growth, IC50 9.9 μM.</p>Fórmula:C22H20N2OCor e Forma:SolidPeso molecular:328.41JAK1/TYK2-IN-3
<p>JAK1/TYK2-IN-3, orally active, selectively inhibits TYK2 (IC50: 6 nM), JAK1 (37 nM), JAK2 (140 nM), JAK3 (362 nM), and has anti-inflammatory effects.</p>Cor e Forma:SolidGDC-0339
CAS:<p>GDC-0339: oral Pim kinase inhibitor for multiple myeloma (Kis: Pim1 - 0.03 nM, Pim2 - 0.1 nM, Pim3 - 0.02 nM), well-tolerated.</p>Fórmula:C20H22F3N7OSCor e Forma:SolidPeso molecular:465.5PARP-1/HDAC-IN-1
CAS:<p>PARP-1/HDAC-IN-1 is a PARP-1 and HDAC6 inhibitor with anticancer, antimigratory, and antiangiogenic activities and is used in tumor research.</p>Fórmula:C22H18N4O4Pureza:95.94%Cor e Forma:SolidPeso molecular:402.4PRMT5-MTA-IN-3
CAS:<p>PRMT5-MTA-IN-3 (Compound P2A) is an orally active and selective inhibitor of protein arginine methyltransferase 5 (PRMT5). It inhibits the proliferation of MTAP-deficient colorectal cancer HCT-116 cell line with an IC50 value of 5 nM. PRMT5-MTA-IN-3 holds potential for research in cancers, particularly in MTAP-deficient tumors such as colorectal cancer, non-small cell lung cancer, and pancreatic cancer.</p>Fórmula:C19H17F3N6O3Cor e Forma:SolidPeso molecular:434.372Pociredir
CAS:<p>Pociredir (FTX-6058), a potent EED inhibitor (KD=0.163 nM), may help in SCD research.</p>Fórmula:C22H18FN5O2Cor e Forma:SolidPeso molecular:403.41LSD1-IN-22
<p>LSD1-IN-22: potent LSD1 inhibitor, K_i 98 nM, curbs cancer cell growth.</p>Fórmula:C9H8BrF2NCor e Forma:SolidPeso molecular:248.07I-BET282E
<p>I-BET282E inhibits eight BET bromodomains (pIC50 6.4-7.7) with selectivity for other bromodomain proteins.</p>Fórmula:C26H34N4O7SCor e Forma:SolidPeso molecular:546.64MS117
<p>MS117 is a first-in-class and cell-active irreversible covalent inhibitor of protein arginine methyltransferase 6 (PRMT6) (IC50 = 18 nM) [1].</p>Fórmula:C17H22N4OCor e Forma:SolidPeso molecular:298.38
